Literature DB >> 12536197

Antitumor effect of secreted Flt3-ligand can act at distant tumor sites in a murine model of head and neck cancer.

Jian Dong1, Robert J Bohinski, Ya-Qin Li, Carter Van Waes, Fred Hendler, Lyon Gleich, Peter J Stambrook.   

Abstract

The Flt3 ligand (Flt3-L) manifests antitumor activity, presumably due to its capacity to recruit dendritic cells and cause their proliferation. To assess whether local production of Flt3-L can mediate a "distant bystander" effect, murine B4B8 squamous cell carcinoma cells were transfected with a plasmid encoding a secretory form of Flt3-L to produce B4B8FL cells. Similarly, B4B8FL and B4B8 cells were transfected with herpes simplex virus thymidine kinase (HSVTK) to produce B4B8TK and B4B8FL/TK cells, which should be sensitive to ganciclovir (GCV), to know whether the effects of Flt3-L and HSVTK/GCV would be synergistic. To test for a distant bystander effect in vivo, B4B8FL, B4B8TK, and B4B8FL/TK cells were injected subcutaneously into the left flank of syngeneic Balb/c mice, and naïve B4B8 cells were injected into the right flank. The formation of tumors derived from B4B8FL and B4B8FL/TK cells was significantly delayed in both flanks compared with naïve B4B8 and B4B8TK cells. Growth of B4B8TK tumors in the ipsilateral flank was retarded following GCV treatment, but in contrast to B4B8FL and B4B8FL/TK cells, no distant bystander effect in the contralateral flank was observed. Immunohistochemistry showed lymphocytic infiltrates in both flanks of the B4B8FL and B4B8FL/TK groups. The data indicate that in these cells, local secretion of Flt3-L is sufficient to evoke a distant bystander effect but that expression of HSVTK, even after GCV administration, is not. Furthermore, the combination of local Flt3-L and HSVTK production, together with GCV administration, does not enhance the distant bystander effect produced by Flt3-L alone.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12536197     DOI: 10.1038/sj.cgt.7700534

Source DB:  PubMed          Journal:  Cancer Gene Ther        ISSN: 0929-1903            Impact factor:   5.987


  4 in total

1.  Phase II trial of bevacizumab with dose-dense paclitaxel as first-line treatment in patients with advanced ovarian cancer.

Authors:  Nicole D Fleming; Robert L Coleman; Celestine Tung; Shannon N Westin; Wei Hu; Yunjie Sun; Priya Bhosale; Mark F Munsell; Anil K Sood
Journal:  Gynecol Oncol       Date:  2017-08-01       Impact factor: 5.482

2.  In Vivo Effects of Conditioned Medium from Human Uterine Cervical Stem Cells in an Ovarian Cancer Xenograft Mouse Model.

Authors:  Juan Sendon-Lago; Samuel Seoane; Fatima Saleh; Lucia Garcia-Caballero; Maria E Arias; Noemi Eiro; Manuel Macia; Francisco J Vizoso; Roman Perez-Fernandez; Jose Schneider
Journal:  Cancer Genomics Proteomics       Date:  2022 Sep-Oct       Impact factor: 3.395

3.  Effect of Flt3 ligand gene transfer in experimental pancreatic cancer.

Authors:  E Ryschich; G Huszty; N Wentzensen; E Schmidt; H P Knaebel; J Encke; A Märten; M W Büchler; J Schmidt
Journal:  Int J Colorectal Dis       Date:  2006-03-10       Impact factor: 2.571

4.  How does ionizing irradiation contribute to the induction of anti-tumor immunity?

Authors:  Yvonne Rubner; Roland Wunderlich; Paul-Friedrich Rühle; Lorenz Kulzer; Nina Werthmöller; Benjamin Frey; Eva-Maria Weiss; Ludwig Keilholz; Rainer Fietkau; Udo S Gaipl
Journal:  Front Oncol       Date:  2012-07-25       Impact factor: 6.244

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.